Page 69 - Binder2
P. 69
According to a 2023 Gallup poll, only 18% of Americans
held a positive view of the pharmaceutical industry, while
60% viewed it negatively. This marked a significant
decline from previous years, highlighting growing public
skepticism. Patients begin to see these therapies not as
breakthroughs, but as cycles of disappointment. Payers
begin to scrutinize costs more skepticism. Patients become
more cautious. And the industry—whether it admits it or
not—pays the price.
Because the actions of the dominant few don’t just shape
their own profit margins.
They shape public perception, payer skepticism, and
prescriber fatigue across the entire field.
When one blockbuster drug overpromises and
underdelivers, it casts a shadow that the rest of the industry
has to live under.
That’s the risk of tolerization staying in the shadows.
It’s not just a clinical problem.
It’s a reputational time bomb.
And if the biologics industry wants to preserve the trust it’s
built—if it wants patients to believe in the next generation
of therapies—it can’t afford another generation of silent
failures.
It needs to lead with clarity, build with durability, and
finally design for the immune system, not around it.
Because without trust, even the most brilliant molecule is
just another broken promise.
67
